RMI and FAF helpful in characterizing retinal dystrophies

Article

Using retro-mode imaging (RMI) and fundus autofluorescence (FAF) can be helpful in characterizing retinal dystrophies.

Using retro-mode imaging (RMI) and fundus autofluorescence (FAF) can be helpful in characterizing retinal dystrophies, according to a paper featured in the journal Bio Med. Central Ophthalmology.

A team led by Dr Battaglia Parodi Maurizio, Department of Ophthalmology, University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy, included 18 consecutive patients with retinal dystrophies.

Each participant underwent ophthalmological assessments including best corrected visual acuity with ETDRS charts, blue-light fundus autofluorescence, (BL-FAF), near-infrared fundus autofluorescence (NIR-FAF) and RMI. The primary outcome was abnormal patterns on RMI and the secondary outcome was the correlation between BL-FAF findings and NIR-FAF findings.

The results revealed that the main feature of RMI is represented by a pseudo-3D pattern of all the posterior pole lesions. There were no fixed correlations between RMI, BL-AF and NIR-AF imaging. The non-invasive diagnostic tools could obtain additional information on clinical setting and patients monitoring.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.